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Abstract
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies
have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their
national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-
limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability,
affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great
promise to simplify treatment in the short term. Over the longer term, newer technologies, such as long-acting formulations and
nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert
consultation on treatment scale up in resource-limited settings.
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Introduction
Recent global commitments aim to provide antiretroviral
therapy (ART) to 15 million people living with HIV by 2015,
but with current coverage at around 50%, and with interna-
tional funding for HIV/AIDS on the decline, there is an
enormous task ahead [1].
Yet, expectations of antiretroviral (ARV) medications have
never been higher.The massive scale up of access to ARTover
the last decade has demonstrated the feasibility of delivering
ART as a public health intervention, with an estimated 2.5
million deaths averted since 1995 [2]. More recent studies
have demonstrated the potential for widespread ART use to
reduce HIV transmission at the population level, findings
that offer enormous opportunities to reverse the epidemic.
Similarly, options for ART have never been greater: there are
now 27 US FDA-approved ARVs collectively targeting five
different points in the HIV life cycle [3].
The need to diagnose more people earlier in their disease
progression, ensure rapid linkage to care, and improve
strategies for retention in care and adherence to ART
continue to be important challenges. Improvements in
uptake and long-term adherence to treatment will likely
depend on improved access to the best available ART
regimens [4]. To direct clinical research, future guidelines
and advocacy efforts, it is critical to develop priority
treatment options, particularly for resource-limited settings.
In September 2011, Medicines Sans Frontie `res, SOLTHIS
(Solidarity The ´rapeutique & Initiatives contre le SIDA) and
Esther (Ensemble pour une solidarity The ´rapeutique Hospi-
talie `re en Re ´seau) organized an expert consultation to
provide recommendations on ARV regimens and strategies
to support further scale-up of treatment in resource-limited
settings [5].
This workshop took place as part of a broader set of
initiatives aiming to develop a vision for the further
simplification of ART in the medium and long term. Of
particular note are two meetings on the strategic use of ARVs
for treatment and prevention of HIV, convened by the
World Health Organization (WHO) under the Treatment 2.0.
Strategy [6]: a conference on short-term priorities for ART
optimization that took place in April 2011 [7] and two
consultations on the strategic use of ARVs for treatment and
prevention held in November 2011 and May 2012 [8].
This viewpoint summarizes the main consensus recom-
mendations from the workshop.The most important research
questions relating to priority ARV drugs and research ques-
tions for resource-limited settings emerging from the meeting
are summarized in Table 1.
Target characteristics of future treatment
regimens
Clinical drug development aims primarily to achieve ther-
apeutic efficacy. Efficacy is an important precondition for any
successful regimen and is particularly important in develop-
ing countries where access to viral load monitoring and
genotyping remain limited. Nevertheless, delivering ART in
resource-limited settings requires more than efficacious
drugs. With effective therapy, people living with HIV can
expect a near normal lifespan [9,10]. Therefore, long-term
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1treatment strategies, including a sequence of regimens that
will provide effective treatment over decades, are required.
Six key principles guide ART choice: simplicity, tolerability
and safety, durability, universal applicability, affordability and
heat stability.
Simplicity
To expand access, many countries have simplified HIV care
so that it can be delivered at primary health care centres by
nurses or community health workers. In such decentralized
settings, simple regimens, prioritizing fixed-dose combina-
tions (FDCs), once-daily formulations, drugs that can be given
weekly or monthly and regimens with minimal laboratory
monitoring, food or fluid requirements, are required [11].
Tolerability and safety
Side effects are a major driver of poor adherence, drug
substitution and treatment discontinuation, all of which
undermine treatment and prevention efforts [12,13]. In
particular, providing ART as prevention implies giving ART
to people who may not yet have experienced clinical illness
and may therefore be more reluctant to adhere to drugs with
side effects.
Durability
With effective therapy, people living with HIV are likely to
take ART for several decades after HIV diagnosis, far longer
than the average life span of most older-generation ARVs.
To maximize durability, drugs must have a high genetic
barrier to resistance mutations. ART must continue to be
provided with an appropriate amount of adherence educa-
tion and counselling, long-term support and follow up.
Nevertheless, to cope with the increasing caseload, models
of care that rely on less frequent clinic visits for stable
patients are likely to become increasingly popular [14], and in
these contexts durability becomes more important.
Universal applicability
Current regimens require frequent substitutions according
to age, pregnancy presence of comorbidities and interactions
with other drugs.The ideal regimen would be one that is safe
and effective, irrespective of disease stage, usable through-
out pregnancy, appropriate for infants, children and adults,
and can be taken together with drugs for co-infections,
notably tuberculosis and viral hepatitis [15].
Affordability
Strategies that lower treatment costs should be prioritized.
These include dose reduction, improved drug bioavailability,
cost reduction of active pharmaceutical ingredient through
improved chemistry process and novel drug delivery systems.
Heat stability
Finally, drug formulations need to be stable without the need
for refrigeration.
Short-term recommendations (Onethree years)
First line antiretroviral therapy
Considering the above six key principles, the preferred
first-line regimen for adults and adolescents is the WHO-
recommended combination of tenofovir (TDF), lamivudine
(3TC) and efavirenz (EFV), available as a once-daily FDC [7].
However, three issues must be overcome to further expand
its use: safety of efavirenz in pregnancy, tenofovir toxicity and
cost reduction.
EFV has been associated with potential teratogenicity
following data from animal models and case reports. To
date, however, rates of congenital abnormalities associated
with EFV are no greater than the background rate [16]. A
pragmatic approach has recently been put forward by WHO
recognizing the important advantages of EFV within a once-
daily regimen and the consequences of switching to poten-
tially less safe and efficacious alternatives, such as nevirapine
[17]. TDF is associated with long-term renal and bone
toxicities and increased risk of fracture [18], but the clinical
Table 1. Priority ARV drugs and research questions
H Issue Research agenda
Efavirenz
Safety in pregnancy Prospective birth registries
Cost Dose optimization
Tenofovir Toxicity (renal and bone)
Long-term cohort reporting
Dose optimization
Cost Development of other pro-drugs
Lopinavir/ritonavir
Poor palatability for infants Development of sprinkles
Cold chain Heat stable formulations
Darunavir, raltegravir, etravirine
Preferential pricing
High cost Market competition
Dose optimization
Long-acting formulations Long-acting regimens required Prioritize development of molecules that can be
combined to form a regimen
Nanotechnology Poor linkage between science and clinical need Priority research agenda to be established
Novel delivery systems Not yet developed Long-acting formulations, patches, injections and
implants
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2significance of these toxicities remains unclear [16] and the
overall riskbenefit equation favours prioritization of this
drug with ongoing monitoring and reporting of adverse
events [19].
The recent approval of TDF for children over two years of
age creates possibilities to align recommendations for adults
and children. An ideal formulation for first-line treatment of
children over three years would be a scored, adult-strength,
dispersible FDC tablet of TDF/3TC/EFV. Treatment pro-
grammes could then use the same pill for almost all patients.
For children below three years of age, protease inhibitors will
remain the preferred strategy given the lack of safety data for
EFV and TDF in infants, non-nucleoside reverse transcription
inhibitor (NNRTI) exposure from prevention of mother to
child transmission and the potential failure of a NNRTI-based
regimen in the HIV-positive mother. To overcome this issue,
better co-formulations of lopinavir/ritonavir (LPV/r) are
needed. A strategy for transitioning children from paediatric
regimens to adult regimens once they reach the age of three
needs to be defined.
Several ongoing studies could potentially lead to lower
costs for EFV and TDF. These include an EFV dose reduction
trial, reformulation and clinical evaluation of tenofovir pro-
drugs CMX157 and GS 7340 [20]. These studies may also
demonstrate reduced drug-related side effects.
Second-line antiretroviral therapy
While improving first-line therapy should improve long-
term adherence to treatment at scale, some patients will
develop treatment failure and will need a directed sequence
of safe, independent (in terms of resistance) and convenient
regimens.
In the short term, the preferred regimen will likely remain
protease inhibitor-based: heat stable co-formulated atazana-
vir plus ritonavir low dose (ATV/r) or darunavir/ritonavir
(DRV/r), which should lower the pill burden and permit once-
daily doses. Incompatibility of these drugs with rifampicin in
tuberculosis regimens is a limitation, but this could be
resolved by replacing rifampicin with rifabutin [21].
As an immediate priority, the price of new drugs currently
used in third-line line regimen, notably darunavir (DRV),
etravirine (ETV) and raltegravir (RAL) needs to decrease
substantially so that second-line treatment can be improved
and become widely available. Dolutegravir (DTG), a pipeline
once-daily integrase inhibitor, is a promising future option,
with the relatively low cost of its active pharmaceutical
ingredient raising the potential for inexpensive manufacture
[22]. Finally, to support adherence to first-line treatment and
detect timely treatment failure, increased access to simple,
affordable viral load measurement is a high priority.
Mid- to long-term recommendations (threeten
years)
For patients initiating antiretroviral treatment
TDF (or alternative pro-drugs of TDF)/3TC/EFV may remain
the preferred option for resource-limited settings for the
medium term. Newer FDCs, including the recently FDA-
approved QUAD† (elvitegravir, cobicistat, tenofovir and
emtricitabine) or rilpivirine-based regimen also available in
once-daily FDC will need careful assessment for use in
resource-limited settings. DTG co-formulated with abacavir
and 3TC is likely to become another single daily co-
formulated pill, although cost may remain an issue. A first-
line regimen with a high genetic barrier to resistance is
preferable, and once-daily ATV/r or DRV/r could be options as
first-line anchor drugs, but these drugs need to be developed
as affordable FDCs. An FDC of darunavir, cobicistat, tenofovir
and emtricitabine is currently under development, but the
price is yet to be determined [23].
Subsequent treatment options
Regimens that have minimal cross-resistance after first-line
failure, and therefore limit the need for virus genotyping, are
a priority. A DRV/r- or DTG-based regimen co-formulated
with a PI (assuming continued successful development of
DTG) for adults, and hopefully also for children failing PI
regimens, meets this requirement. Implementation will
require a strategic decision on when to use DRV and DTG
for optimal benefit (as first- or second-line option).
In the longer term, a numberofemerging new technologies
have the potential to revolutionize ART. Long-acting formula-
tions offer the promise of weekly or even monthly therapy,
which could improve patient adherence and health service
efficiencies, such as prescriptions, drug supply and pharmacy
management. Numerous drugs, including rilpivirine, S/GSK
744 and CMX 157, are already in clinical development as long-
acting drugs, although the potential for combining several
drugs into a single long-acting combination therapy remains
unexplored [22]. Novel delivery systems, including patches,
implants and injections, are also under development and
could potentially improve adherence. Finally, nanotechnology
holds promise for better treatments by enhancing drug
activity, improving toxicity profiles and reducing cost (by
reducing the amount of active ingredient). A nanosuspension
of rilpivirine is currently in development. The clinical chal-
lenges related to the implementation of these delivery
systems will require careful assessment.
Conclusions
Countries are increasingly adapting their national guidelines
to start ART earlier, for both clinical and preventive benefits.
Providing people with affordable medicines, combined into
effective regimens with as few side effects as possible and in
a form that is practical to take and easy to adhere to, remains
a challenge. But this challenge must be met in order to
improve patient outcomes and reap the preventive benefits
of widespread ART coverage.
These considerations raise the stakes for the ongoing
WHO-facilitated discussions on implementation of the
Treatment 2.0 strategy [6] and the update process of WHO
ART guidelines (planned for release in 2013), which will
define the optimized choices of ART management in a public
health approach. This implies prioritizing ART regimens to
ensure that patient treatment, programme management and
drug procurement are all simplified as far as possible. These
issues are particularly critical to the policy environment in
which decisions are made about key levers (such as local drug
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price of drugs.
People living with HIV, treatment providers and high-
prevalence communities have a stake in these decisions
about how HIV will be managed in the coming years. A key
challenge is how much (and at what cost) to optimize
treatment for individuals while expanding it to as many
people as possible. Currently, constrained budgets should not
lead to compromising the quality of treatments that achieve
and maintain viral suppression that will benefit the health
of both individuals and communities.
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